Patents by Inventor Gary McLean

Gary McLean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Induction of cross-reactive cellular response against rhinovirus antigens
    Patent number: 9937252
    Abstract: The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: April 10, 2018
    Inventors: Gary McLean, Walton Ross, Sebastian Johnston, Nathan Wylie Bartlett, Bruno Guy, Yves Girerd-Chambaz, Valerie Lecouturier, Jeffrey Almond, Nicholas Glanville, Nicolas Burdin
  • INDUCTION OF CROSS-REACTIVE CELLULAR RESPONSE AGAINST RHINOVIRUS ANTIGENS
    Publication number: 20160095916
    Abstract: The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.
    Type: Application
    Filed: February 6, 2014
    Publication date: April 7, 2016
    Applicants: SANOFI PASTEUR, IMPERIAL INNOVATIONS LIMITED
    Inventors: Gary McLean, Walton Ross, Sebastian Johnson, Nathan Bartlett, Bruno Guy, Yves Girerd-Chambaz, Valerie Lecouturier, Jeffrey Almond, Nicholas Glanville, Nicolas Burdin